Breaking Medical Technology News: Aethlon
Medical (NASDAQ: $AEMD) Announces Publication of Preclinical Data Showing
Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs
from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded
Donor Kidneys
Results Support Future
Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further
Assess its Association with Function of Retrieved Kidneys
SAN DIEGO,
CA - August 27, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing
products to treat cancer and life-threatening infectious diseases, today
announced the publication in preprint of an in vitro study in bioRxiv on August
24, 2024, entitled, "The Hemopurifier® Removes Extracellular Vesicles and
microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of
Discarded Donor Kidneys."
Aethlon Medical's Hemopurifier® is a therapeutic blood
filtration system designed to bind and remove harmful exosomes and life-threatening
viruses from blood and other biological fluids, qualities which have potential
applications in oncology and infectious diseases, as well as in the organ
transplant setting.
This news is paid advertisement/ news disseminated
on behalf of/issued on behalf of Aethlon Medical Inc.
Read
this news, featuring AEMD in full at https://www.investorideas.com/news/2024/08271AEMD-Hemopurifier-Preclinical-data.asp
"Kidney transplantation provides the highest
quality of life for those afflicted with end stage renal disease, yet a
significant shortage in the number of donor kidneys currently exists,"
stated Steven LaRosa, MD, Senior Author of the paper and Chief Medical Officer
of Aethlon Medical. "To bridge the gap between recipients and donors, the
criteria for the use of kidneys from deceased brain death and diseased circulatory
death donors has been extended. However, kidneys from extended criteria donors
are associated with higher rates of poor graft function and acute rejection in
recipients. The release of extracellular vesicles (EVs) and microRNAs from the
donor kidney are hypothesized to play a role in these complications and are
targets for the, Hemopurifier®."
Given that one approach to lessen these complications
and potentially increase the time of assessment of organ viability is to use
machine perfusion on recovered kidneys, and, based on Aethlon Medical's prior
data in COVID-19 and oncology, it was hypothesized that the Hemopurifier® could
remove EVs and microRNAs from renal perfusates. In this proof-of-concept study,
the company obtained four perfusates from discarded donor kidneys that had
undergone a type of machine perfusion called Controlled Oxygenated Rewarming
(COR). These perfusates were then pumped over the Hemopurifier® and analyzed
for EV counts and microRNA levels. The results confirmed the removal of both
small and larger size EVs and a significant reduction in microRNAs.
"While our primary focus is to conduct our
planned clinical trials of the Hemopurifier® in India and Australia, in
patients with solid tumors who have stable or progressive disease during anti-PD-1
monotherapy, the data generated by this proof-of-concept study is encouraging
and provides evidence for adding the transplant indication to our product
pipeline," added James Frakes, Interim Chief Executive Officer and Chief
Financial Officer of Aethlon Medical. "Next steps to consider would be an
additional pre-clinical study comparing mediator removal, renal function and
histopathology in a machine perfusion circuit performed both with and without
incorporation of the Hemopurifier® on discarded kidneys.
Ultimately, a clinical trial designed to demonstrate
that incorporation of the Hemopurifier® into renal perfusion improves important
clinical endpoints in transplant recipients such as delayed graft function,
graft survival or rejection rates would likely be required."
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening viral infections
and for use in organ transplantation. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and in pre-clinical
studies, the Hemopurifier has demonstrated the removal of harmful exosomes from
biological fluids, utilizing its proprietary lectin-based technology. This
action has potential applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious diseases. The
Hemopurifier is a U.S. Food and Drug Administration (FDA) designated
Breakthrough Device indicated for the treatment of individuals with advanced or
metastatic cancer who are either unresponsive to or intolerant of standard of
care therapy, and with cancer types in which exosomes have been shown to
participate in the development or severity of the disease. The Hemopurifier
also holds an FDA Breakthrough Device designation and an open Investigational
Device Exemption (IDE) application related to the treatment of life-threatening
viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 that involve risks and uncertainties.
Statements containing words such as "may," "believe,"
"anticipate," "expect," "intend,"
"plan," "project," "will,"
"projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never materialize
or may prove to be incorrect. Factors that may contribute to such differences
include, without limitation, the Company's ability to raise additional capital
and to successfully complete development of the Hemopurifier; the Company's
ability to successfully demonstrate the utility of the Hemopurifier in cancer
and infectious diseases and in the transplant setting; the Company's ability to
achieve and realize the anticipated benefits from potential milestones; the
Company's ability to submit applications to and obtain approval from the
additional Ethics Committees in Australia and India, including on the timing
expected by the Company; the Company's ability to initiate its planned oncology
clinical trials in Australia and India, including on the timing expected by the
Company; the Company's ability to manage and successfully complete its clinical
trials, if initiated; the potential impact of Hemopurifier on the H5N1 Avian
Influenza (H5N1 HPAI) virus in dairy cattle; the Company's ability to
successfully manufacture the Hemopurifier in sufficient quantities for its
clinical trials, and other potential risks. The foregoing list of risks and
uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended
March 31, 2024, and in the Company's other filings with the Securities and
Exchange Commission, including its quarterly Reports on Form 10-Q. All
forward-looking statements contained in this press release speak only as of the
date on which they were made. Except as may be required by law, the Company
does not intend, nor does it undertake any duty, to update this information to
reflect future events or circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
SOURCE Aethlon
Medical, Inc.
Aethlon
Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com
More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News
Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Biotech Industry Stocks- investing ideas
in biotechnology stocks, medical technology and life sciences
No comments:
Post a Comment